Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
19.77 ^USD	-1.69%		+1.23%	+12.71%

May. 14	Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM
Apr. 23	Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises	MT

Kiniksa Pharmaceuticals, Ltd. Updates Earnings Guidance for 2024

April 23, 2024 at 07:35 am EDT

Kiniksa Pharmaceuticals, Ltd. updated earnings guidance for 2024. For the period, the company expects ARCALYST net product revenue of between $370 million and $390 million, compared to prior guidance of between $360 million and $380 million.

Latest news about Kiniksa Pharmaceuticals, Ltd.

Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM	May. 14
Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises	Apr. 23	MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024	Apr. 23
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Posts Q1 Revenue $79.9M, vs. Street Est of $78.5M	Apr. 23	MT
Kiniksa Pharmaceuticals, Ltd. Updates Earnings Guidance for 2024	Apr. 23	CI
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Wedbush Adjusts Kiniksa Pharmaceuticals' PT to $30 From $28, Maintains Outperform Rating	Apr. 03	MT
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart	Apr. 02	CI
Kiniksa Pharmaceuticals' Q4 Earnings, Revenue Increase	Feb. 28	MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q4 Revenue $83.4M, vs. Street Est of $72.3M	Feb. 28	MT
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for the Year 2024	Jan. 08	CI
Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 01:30 PM	Jan. 08
Wedbush Lifts Kiniksa Pharmaceuticals' PT to $25 From $23 Ahead of Planned Q1 Reporting of Initial Data on KPL-404; Maintains Outperform Rating	Jan. 02	MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q3 2023 Earnings Call, Oct 31, 2023	23-10-31
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q3 Revenue $67M, vs. Street Est of $64.4M	23-10-31	MT
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023	23-10-31	CI
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Insider Sell: Kiniksa Pharmaceuticals	23-07-27	MT
Sector Update: Health Care Stocks Steady in Late Afternoon Trading	23-07-25	MT
Sector Update: Health Care	23-07-25	MT
Kiniksa Pharmaceuticals' Shares Rise as Q2 Net Income, Revenue Advance	23-07-25	MT
Top Midday Gainers	23-07-25	MT
Wedbush Adjusts Kiniksa Pharmaceuticals Price Target to $23 From $21, Maintains Outperform Rating	23-07-25	MT

Chart Kiniksa Pharmaceuticals, Ltd.

Duration

Period

More charts

Company Profile

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1Î±), and interleukin-1beta (IL-1Î²), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRÎ±).

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Extraordinary Shareholders Meeting - Reincorporation Vote

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Kiniksa Pharmaceuticals, Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.77 USD

Average target price

30.67 USD

Spread / Average Target

+55.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KINIKSA PHARMACEUTICALS, LTD.	+12.71%	1.4B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.84B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
BEIGENE, LTD.	-4.16%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs